Sign in Subscribe

Armata Pharmaceuticals Shows Promising Results for AP-SA02 in Severe Staph Infection

Armata's AP-SA02 bacteriophage cocktail showed high cure rates and zero relapse in a Phase 2 trial for complicated Staphylococcus aureus bacteremia (SAB), signaling a potential new standard of care.

Armata Pharmaceuticals Shows Promising Results for AP-SA02 in Severe Staph Infection
Photo by National Institute of Allergy and Infectious Diseases on Unsplash
Already have an account? Sign in.